Published in Transl Androl Urol on June 01, 2012
Anacardic acid (6-pentadecylsalicylic acid) induces apoptosis of prostate cancer cells through inhibition of androgen receptor and activation of p53 signaling. Chin J Cancer Res (2012) 0.86
Effects of sulforaphane and 3,3'-diindolylmethane on genome-wide promoter methylation in normal prostate epithelial cells and prostate cancer cells. PLoS One (2014) 0.83
Genomic profiling screens small molecules of metastatic prostate carcinoma. Oncol Lett (2015) 0.82
TGF-β1 epigenetically modifies Thy-1 expression in primary lung fibroblasts. Am J Physiol Cell Physiol (2015) 0.77
Genome-wide DNA methylation identifies trophoblast invasion-related genes: Claudin-4 and Fucosyltransferase IV control mobility via altering matrix metalloproteinase activity. Mol Hum Reprod (2015) 0.76
Identification of Predictive DNA Methylation Biomarkers for Chemotherapy Response in Colorectal Cancer. Front Pharmacol (2017) 0.75
Hepatitis viruses exploitation of host DNA methyltransferases functions. Clin Exp Med (2015) 0.75
Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell (2003) 25.94
Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res (2004) 3.29
cDNA cloning and sequence analysis of beta ig-h3, a novel gene induced in a human adenocarcinoma cell line after treatment with transforming growth factor-beta. DNA Cell Biol (1992) 2.91
EphB receptor activity suppresses colorectal cancer progression. Nature (2005) 2.84
Caveolin-1 regulates transforming growth factor (TGF)-beta/SMAD signaling through an interaction with the TGF-beta type I receptor. J Biol Chem (2000) 2.56
Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers. Proc Natl Acad Sci U S A (2008) 2.53
Non-Smad signaling pathways. Cell Tissue Res (2011) 2.52
Functional epigenomics identifies genes frequently silenced in prostate cancer. Cancer Res (2005) 2.37
New regulatory mechanisms of TGF-beta receptor function. Trends Cell Biol (2009) 2.34
Programming of DNA methylation patterns. Annu Rev Biochem (2012) 2.32
WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer. J Pathol (2003) 2.30
Cancer epigenomics: beyond genomics. Curr Opin Genet Dev (2012) 2.11
Identification of an mRNP complex regulating tumorigenesis at the translational elongation step. Mol Cell (2011) 1.80
Methylation and gene silencing of the Ras-related GTPase gene in lung and breast cancers. Ann Surg Oncol (2006) 1.79
The role of RASSF1A methylation in cancer. Dis Markers (2007) 1.73
Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia. J Pathol (2004) 1.72
Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer. J Mol Med (Berl) (2006) 1.72
TGF-beta promotes Th17 cell development through inhibition of SOCS3. J Immunol (2009) 1.66
Epigenetic reprogramming of cancer cells via targeted DNA methylation. Epigenetics (2012) 1.65
TGFbeta-induced downregulation of E-cadherin-based cell-cell adhesion depends on PI3-kinase and PTEN. J Cell Sci (2005) 1.63
Cited2 controls left-right patterning and heart development through a Nodal-Pitx2c pathway. Nat Genet (2004) 1.61
Changes in prostate gene expression in men undergoing an intensive nutrition and lifestyle intervention. Proc Natl Acad Sci U S A (2008) 1.61
Epigenetic regulation of cancer stem cell marker CD133 by transforming growth factor-beta. Hepatology (2010) 1.60
Promoter methylation in APC, RUNX3, and GSTP1 and mortality in prostate cancer patients. J Clin Oncol (2009) 1.58
Protein phosphatase 2A is a critical regulator of protein kinase C zeta signaling targeted by SV40 small t to promote cell growth and NF-kappaB activation. EMBO J (1997) 1.57
Absolute quantitation of DNA methylation of 28 candidate genes in prostate cancer using pyrosequencing. Dis Markers (2011) 1.56
Epigenetic alterations in human prostate cancers. Endocrinology (2009) 1.55
Smad3 reduces susceptibility to hepatocarcinoma by sensitizing hepatocytes to apoptosis through downregulation of Bcl-2. Cancer Cell (2006) 1.54
Epigenetics in prostate cancer: biologic and clinical relevance. Eur Urol (2011) 1.49
Identification of novel tumor markers in prostate, colon and breast cancer by unbiased methylation profiling. PLoS One (2008) 1.46
Retracted DNA methylation-associated inactivation of TGFbeta-related genes DRM/Gremlin, RUNX3, and HPP1 in human cancers. Br J Cancer (2005) 1.45
Retracted Methylation of apoptosis related genes in the pathogenesis and prognosis of prostate cancer. Cancer Lett (2006) 1.40
Methylation mediated silencing of TMS1/ASC gene in prostate cancer. Mol Cancer (2006) 1.38
Epigenetics in breast cancer: what's new? Breast Cancer Res (2011) 1.36
DNA methylation biomarkers for lung cancer. Tumour Biol (2011) 1.35
EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients. Carcinogenesis (2010) 1.34
Cutting edge: TGF-beta-induced expression of Foxp3 in T cells is mediated through inactivation of ERK. J Immunol (2008) 1.34
Genetic and epigenetic alterations in pancreatic carcinogenesis. Curr Genomics (2011) 1.33
Inhibition of the extracellular signal-regulated kinase/mitogen-activated protein kinase pathway decreases DNA methylation in colon cancer cells. J Biol Chem (2007) 1.31
Sox7 Is an independent checkpoint for beta-catenin function in prostate and colon epithelial cells. Mol Cancer Res (2008) 1.30
High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients. Clin Cancer Res (2007) 1.30
Dietary and lifestyle factors of DNA methylation. Methods Mol Biol (2012) 1.30
The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer. Oncogene (2010) 1.29
Regulation of beta 4-integrin expression by epigenetic modifications in the mammary gland and during the epithelial-to-mesenchymal transition. J Cell Sci (2009) 1.25
RTVP-1, a tumor suppressor inactivated by methylation in prostate cancer. Cancer Res (2004) 1.25
The role of EZH2 in the regulation of the activity of matrix metalloproteinases in prostate cancer cells. PLoS One (2012) 1.25
CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer. Urology (2008) 1.24
Glutathione S-transferase pi (GSTP1) hypermethylation in prostate cancer: review 2007. Pathology (2007) 1.24
Genistein reverses hypermethylation and induces active histone modifications in tumor suppressor gene B-Cell translocation gene 3 in prostate cancer. Cancer (2010) 1.23
Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci. Clin Cancer Res (2005) 1.22
Review: molecular pathology of cyclooxygenase-2 in cancer-induced angiogenesis. Ann Clin Lab Sci (2001) 1.21
Inhibitor of differentiation 4 (Id4) is a potential tumor suppressor in prostate cancer. BMC Cancer (2009) 1.20
The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia. J Urol (2007) 1.19
Altered methylation of multiple genes in carcinogenesis of the prostate. Int J Cancer (2003) 1.18
Global methylation pattern of genes in androgen-sensitive and androgen-independent prostate cancer cells. Mol Cancer Ther (2010) 1.16
Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways. Blood (2008) 1.16
Nuclear factor-kappaB-mediated transforming growth factor-beta-induced expression of vimentin is an independent predictor of biochemical recurrence after radical prostatectomy. Clin Cancer Res (2009) 1.16
Concordant epigenetic silencing of transforming growth factor-beta signaling pathway genes occurs early in breast carcinogenesis. Cancer Res (2007) 1.15
Epigenetics of renal cell carcinoma: the path towards new diagnostics and therapeutics. Genome Med (2010) 1.14
Involvement of the TGF-beta and beta-catenin pathways in pelvic lymph node metastasis in early-stage cervical cancer. Clin Cancer Res (2011) 1.13
HIN-1, an inhibitor of cell growth, invasion, and AKT activation. Cancer Res (2005) 1.13
PDLIM4 repression by hypermethylation as a potential biomarker for prostate cancer. Clin Cancer Res (2006) 1.13
Epigenetics of prostate cancer: beyond DNA methylation. J Cell Mol Med (2006) 1.12
Aberrant methylation of EphA7 in human prostate cancer and its relation to clinicopathologic features. Int J Cancer (2009) 1.12
Oocyte-secreted factor activation of SMAD 2/3 signaling enables initiation of mouse cumulus cell expansion. Biol Reprod (2006) 1.09
Evidence for altered Wnt signaling in psoriatic skin. J Invest Dermatol (2010) 1.08
Epigenetic suppression of the TGF-beta pathway revealed by transcriptome profiling in ovarian cancer. Genome Res (2010) 1.08
Hypermethylation of the caveolin-1 gene promoter in prostate cancer. Prostate (2001) 1.08
Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer. J Urol (2010) 1.07
Epigenetic biomarkers in prostate cancer: Current and future uses. Cancer Lett (2012) 1.07
Convergence of p53 and transforming growth factor beta (TGFbeta) signaling on activating expression of the tumor suppressor gene maspin in mammary epithelial cells. J Biol Chem (2007) 1.06
Epigenetic silencing of SOCS3 identifies a subset of prostate cancer with an aggressive behavior. Prostate (2010) 1.06
Promoter methylation of TSLC1 and tumor suppression by its gene product in human prostate cancer. Jpn J Cancer Res (2002) 1.05
Peripheral chondrosarcoma progression is accompanied by decreased Indian Hedgehog signalling. J Pathol (2006) 1.05
Promoter CpG hypermethylation and downregulation of XAF1 expression in human urogenital malignancies: implication for attenuated p53 response to apoptotic stresses. Oncogene (2006) 1.04
Insensitivity to transforming growth factor-beta results from promoter methylation of cognate receptors in human prostate cancer cells (LNCaP). Mol Endocrinol (2005) 1.03
Control of microRNA biogenesis by TGFbeta signaling pathway-A novel role of Smads in the nucleus. Cytokine Growth Factor Rev (2009) 1.02
Methylated genes as potential biomarkers in prostate cancer. BJU Int (2010) 1.02
A critical role for the Sp1-binding sites in the transforming growth factor-beta-mediated inhibition of lipoprotein lipase gene expression in macrophages. Nucleic Acids Res (2005) 1.00
Inactivation of cyclin D2 gene in prostate cancers by aberrant promoter methylation. Clin Cancer Res (2003) 1.00
Functional switching of TGF-beta1 signaling in liver cancer via epigenetic modulation of a single CpG site in TTP promoter. Gastroenterology (2009) 1.00
DNA methylation changes in prostate cancer. Methods Mol Biol (2012) 1.00
Dietary factors and epigenetic regulation for prostate cancer prevention. Adv Nutr (2011) 1.00
Promoter hypermethylation in prostate cancer. Cancer Control (2010) 0.99
Methylation screening of the TGFBI promoter in human lung and prostate cancer by methylation-specific PCR. BMC Cancer (2008) 0.99
Aberrant promoter methylation of laminin-5-encoding genes in prostate cancers and its relationship to clinicopathological features. Clin Cancer Res (2003) 0.99
Hypermethylation of MCAM gene is associated with advanced tumor stage in prostate cancer. Prostate (2008) 0.98
Effect of DNA methylation on identification of aggressive prostate cancer. Urology (2008) 0.98
Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumor grade in human prostate cancer tissues. Clin Cancer Res (1996) 0.98
Aberrant cellular retinol binding protein 1 (CRBP1) gene expression and promoter methylation in prostate cancer. J Clin Pathol (2004) 0.98
IGFBP3 promoter methylation in colorectal cancer: relationship with microsatellite instability, CpG island methylator phenotype, and p53. Neoplasia (2007) 0.98
ALL1 fusion proteins induce deregulation of EphA7 and ERK phosphorylation in human acute leukemias. Proc Natl Acad Sci U S A (2007) 0.97
Downregulation of tight junction-associated MARVEL protein marvelD3 during epithelial-mesenchymal transition in human pancreatic cancer cells. Exp Cell Res (2011) 0.97
Epigenetic deregulation across chromosome 2q14.2 differentiates normal from prostate cancer and provides a regional panel of novel DNA methylation cancer biomarkers. Cancer Epidemiol Biomarkers Prev (2010) 0.97
Disruption of transforming growth factor-beta signaling by five frequently methylated genes leads to head and neck squamous cell carcinoma pathogenesis. Cancer Res (2009) 0.97
Keratoepithelin reverts the suppression of tissue factor pathway inhibitor 2 by MYCN in human neuroblastoma: a mechanism to inhibit invasion. Int J Oncol (2008) 0.97
Fisetin induces apoptosis in human cervical cancer HeLa cells through ERK1/2-mediated activation of caspase-8-/caspase-3-dependent pathway. Arch Toxicol (2011) 0.96
Epigenetic inactivation of the placentally imprinted tumor suppressor gene TFPI2 in prostate carcinoma. Cancer Genomics Proteomics (2010) 0.96
CD44 and PTGS2 methylation are independent prognostic markers for biochemical recurrence among prostate cancer patients with clinically localized disease. Epigenetics (2006) 0.96